Magic™ Human OX40 (TNFRSF4) Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;A549;SPC-A1;HFL1;Jurkat;Raji

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Cancer Research;Immunology Research

Related Diseases

Immunodeficiency 16; Kaposi Sarcoma

Gene ID

Human:7293

UniProt ID

Human:P43489

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

TNFRSF4 (also known as OX40) is a gene that is differentially expressed in various types of cancer, including colorectal cancer, hepatocellular carcinoma, and ovarian cancer. In colorectal cancer, TNFRSF4 is one of the genes that show significant differences in expression between tumor samples and non-tumor controls, suggesting its involvement in carcinogenesis and metastatic potential. In hepatocellular carcinoma, TNFRSF4 is identified as an immune-related prognostic gene that may serve as a biomarker for predicting patient outcomes. In ovarian cancer, TNFRSF4 is found to be significantly differentially expressed between platinum-sensitive and platinum-resistant samples, indicating its potential role in chemotherapy response. These findings suggest that TNFRSF4 may have applications in understanding cancer biology, predicting patient prognosis, and guiding personalized treatment strategies.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for Magic™ Human OX40 (TNFRSF4) Stable Cell Line (S01YF-1023-PY164). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Alex Davis (Verified Customer)

What is the role of TNFRSF4 in immune cell infiltration in cancer? Dec 23 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

TNFRSF4 expression impacts immune cell infiltration and gene mutation frequency in cancers like hepatocellular carcinoma, suggesting its role in tumor immunity and as a prognostic marker. Dec 23 2021

chat Peyton Brown (Verified Customer)

How does TNFRSF4 expression affect the prognosis of endometrial carcinoma? Sep 18 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

TNFRSF4 is a key player in endometrial carcinoma, serving as a potential biomarker for prognosis prediction and immunomodulation. Sep 18 2023

Published Data

Fig.1 Enhanced TNFSF4 expression in fibroblasts fosters in vivo chemoresistance within lung adenocarcinoma, bolstering the tumor's resilience to chemotherapy treatments.

When fibroblast cells were co-implanted in a 1:1 ratio with lung adenocarcinoma cells, the growth of tumors was closely monitored. Remarkably, fibroblast cells that exhibited an enhanced expression of TNFSF4 (HFL-1-TNFSF4) induced a notable resistance to cisplatin in both the SPC-A1 and A549 lung adenocarcinoma models. Intriguingly, this resistance could be effectively reversed by suppressing TNFRSF4 expression in the lung adenocarcinoma cells, as observed in the SPC-A1-TNFRSF4 si and A549-TNFRSF4 si cell lines.

Ref: Li, Yan, et al. "Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells." Cancer Letters 497 (2021): 212-220.

Pubmed: 33132120

DOI: 10.1016/j.canlet.2020.10.032

Research Highlights

Holubekova, Veronika. et al. "Differential gene expression of immunity and inflammation genes in colorectal cancer using targeted RNA sequencing." Frontiers in oncology, 2023.
Colorectal cancer is a heterogeneous disease driven by molecular changes, such as driver mutations and gene methylations. Its progression is influenced by the tumor microenvironment (TME), which contains immune cells with both pro- and anti-tumor effects. Understanding the interactions between the immune system and the TME is crucial for developing effective immunotherapeutic approaches for CRC. Through their study, the researchers examined the expression patterns of inflammatory and immune-related genes to uncover dysregulated signaling pathways involved in cancer development and metastasis, and their connection to the KRAS gene mutation.
Holubekova, Veronika. et al. "Differential gene expression of immunity and inflammation genes in colorectal cancer using targeted RNA sequencing." Frontiers in oncology, 2023.
Pubmed: 37869102 DOI: 10.3389/fonc.2023.1206482

Xu, Sa. et al. "Construction and validation of a immune-related prognostic gene DHRS1 in hepatocellular carcinoma based on bioinformatic analysis." Medicine, 2023.
A member of the short-chain dehydrogenase/reductase superfamily (DHRS1, SDR19C1) has been identified as a potential predictor of hepatocellular carcinoma (HCC). Despite this, the specific role of DHRS1 in HCC immune response is still unclear. Through analysis of transcriptional and clinical data from the Tumor Immune Estimation Resource and cBioPortal databases, researchers systematically examined the association between DHRS1 and HCC immunity. This study identified six DHRS1-associated immunomodulators that strongly correlate with survival and can be used to create a risk score for each patient. External validation sets were employed to confirm the predictive validity of this risk score, and a prognostic nomogram and calibration curve were constructed. These results suggest that the DHRS1 gene may play a role in HCC immunity and the identified immune signature based on DHRS1-associated immunomodulators may serve as a promising prognostic biomarker for HCC.
Xu, Sa. et al. "Construction and validation of a immune-related prognostic gene DHRS1 in hepatocellular carcinoma based on bioinformatic analysis." Medicine, 2023.
Pubmed: 37861541 DOI: 10.1097/MD.0000000000035268